ACE2 News and Research

RSS

SARS-CoV-2 ORF10 degrades mitochondrial antiviral signaling protein to suppress immune response

A novel mechanism by which SARS-CoV-2 inhibits the innate immune response; that is, ORF10 induces mitophagy-mediated MAVS degradation by binding to NIX.

5 Dec 2021

New test can quickly and easily assess antibody effectiveness against COVID-19 variants

Biomedical engineers at Duke University have devised a test to quickly and easily assess how well a person's neutralizing antibodies fight infection from multiple variants of COVID-19 such as Delta and the newly discovered Omicron variant.

4 Dec 2021

Telomeric DNA damage response may increase susceptibility of elderly people to COVID-19

SARS-CoV-2 causes the pandemic coronavirus disease COVID-19, that is more harmful for elderly people, who show more severe symptoms and are at higher risk of hospitalization and death.

3 Dec 2021

Quantum mechanical model offers insights into SARS-CoV-2 evolution

Researchers used an ab initio full quantum mechanical model to characterize the spike protein RBD interactions with host cells and gain mechanistic insights into SARS-CoV-2 evolution.

3 Dec 2021

Novel peptide-antibody fusion molecule enhances SARS-CoV-2 variant neutralization

A recent study reports neutralizing efficacy for a fused peptide-antibody molecule against SARS-CoV-2, providing hope that therapeutic neutralizing antibodies may soon be available.

3 Dec 2021

Green seaweed extract exhibits anti-SARS-CoV-2 activity in vitro

Researchers investigate the antiviral activities of SSPS extracted from green seaweed Ulva sp. to demonstrate the anti-SARS-CoV-2 activity of ulvans.

2 Dec 2021

New bioinformatics method for viral sgRNA analysis

A recent study discusses a bioinformatics method to help identify and explore sgRNAs uncovered in next-generation sequencing data.

2 Dec 2021

Impact of SARS-CoV-2 infection on testis function

A study published in the journal Nature Reviews Urology discusses the impact of coronavirus disease 2019 (COVID-19) on male fertility.

2 Dec 2021

Researchers report antibody cocktails are promising candidate tools for controlling new SARS-CoV-2 variants

Researchers from Academia Sinica in Taiwan have been investigating new antibodies that could have strong effects against SARS-CoV-2 infection.

2 Dec 2021

Natural triterpenoids in licorice found to inhibit SARS-CoV-2

In new studies, researchers concluded that licorice triterpenoids could be candidates for anti-SARS-CoV-2 drug developments.

2 Dec 2021

Impact of engineered ACE2-Fc on SARS-CoV-2 infection

Researchers employ a structure-guided approach for the development of a series of ACE2-Fc variants using human IgG1 or IgG3 backbone.

1 Dec 2021

Structure function analysis of potent antibodies against Beta SARS-CoV-2 variant

A team of researchers from UK and US institutions created a large panel of mAbs derived from memory B cells of convalescent Beta subjects to better understand the antigenic landscape of Beta.

1 Dec 2021

Impact of SARS-CoV-2 on oral health

New research examined SARS-CoV-2 and its impact on oral health and suggests that survival against the infection may be partially dependent on such factors.

1 Dec 2021

Role of interferon type I-driven responses associated with disease control in COVID-19

New research suggests that treatment with type I interferons in the early stage of COVID-19 may supress disease progression by limiting SARS-CoV-2 in hosts.

1 Dec 2021

An antiviral regimen based on biomimetic polymers for COVID-19

In a new study published on the bioRxiv* preprint server, scientists proposed the aforementioned mechanism of action (MOA) and have validated it using electron photomicrographs of murine cytomegalovirus (MCMV), which were incubated with a nanoviricide.

30 Nov 2021

Structure-guided virtual screening identifies novel SARS-CoV-2 Mpro inhibitors

A new paper deals with the identification of an antiviral compound that could help in developing additional drugs to help fight COVID-19.

30 Nov 2021

Human LRRC15 protein is an inhibitory receptor for SARS-CoV-2 spike-mediated entry

In a recent study, published on the bioRxiv* preprint server, researchers identified human LRRC15 as an inhibitory receptor for SARS-CoV-2 entry, which directly binds to the receptor-binding domain (RBD) of the spike protein with a moderate affinity and inhibits spike-mediated entry.

29 Nov 2021

ACE2 News and Research

SARS-CoV-2 ORF10 degrades mitochondrial antiviral signaling protein to suppress immune response

New test can quickly and easily assess antibody effectiveness against COVID-19 variants

Telomeric DNA damage response may increase susceptibility of elderly people to COVID-19

Quantum mechanical model offers insights into SARS-CoV-2 evolution

Novel peptide-antibody fusion molecule enhances SARS-CoV-2 variant neutralization

Green seaweed extract exhibits anti-SARS-CoV-2 activity in vitro

New bioinformatics method for viral sgRNA analysis

Impact of SARS-CoV-2 infection on testis function

Researchers report antibody cocktails are promising candidate tools for controlling new SARS-CoV-2 variants

Natural triterpenoids in licorice found to inhibit SARS-CoV-2

Impact of engineered ACE2-Fc on SARS-CoV-2 infection

Structure function analysis of potent antibodies against Beta SARS-CoV-2 variant

Impact of SARS-CoV-2 on oral health

Role of interferon type I-driven responses associated with disease control in COVID-19

An antiviral regimen based on biomimetic polymers for COVID-19

Structure-guided virtual screening identifies novel SARS-CoV-2 Mpro inhibitors

Human LRRC15 protein is an inhibitory receptor for SARS-CoV-2 spike-mediated entry

Glycosylation and disulfide bonding profile of SARS-CoV-2 spike glycoprotein

Extended host range for SARS-CoV-2 variants of concern

Immunity found 6 months after SARS-CoV-2 infection in children

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News